ClinicalTrials.gg
CompletedNCT03111407Updated Apr 13, 2021Results posted

iAssist vs. Conventional Instrumentation in Total Knee Arthroplasty

An interventional study of total knee arthroplasty in Avascular Necrosis, Post-traumatic; Arthrosis and Knee Osteoarthritis, sponsored by Zimmer, GmbH. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-13.

Sponsored by Zimmer, GmbH · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Apr 2014, registered Apr 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Osteonecrosis by Zimmer Biomet — 3 open to participants now, 15 under way, none of them phase 3. Osteonecrosis · Zimmer Biomet.

Enrollment
12th of 16
72 · median 193
Started
2014
with 2 others
No phase
15 of 57
2 open now
Registered
32nd of 57
by date

Among the 57 studies in Osteonecrosis by Zimmer Biomet, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2014, is one of 15 with no phase, and was the 32nd registered.

Osteonecrosis

287 studies on the registry are indexed under Osteonecrosis; 46 are open to participants now.

Browse Osteonecrosis studies →

Open to participants now

3 of the 57 studies in Osteonecrosis by Zimmer Biomet are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 23 Osteonecrosis studies recruiting now, 14 (61%) set no upper age limit and 4 (17%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Osteonecrosis by Zimmer Biomet, or all of them as a file.
02

Study summary

The purpose of this prospective study is to evaluate Zimmer® iASSIST™ with respect to radiographic, clinical and economic outcomes and compared to conventional instrumentation in primary total knee arthroplasty (NexGen or Persona knee implants).

Read the detailed description

The study design is a prospective, multicenter, comparative outcome study. The study requires each site to obtain IRB (Institutional Review Board) approval prior to study enrollment. All potential study subjects will be required to participate in the Informed Consent Process.

All study subjects will undergo preoperative clinical evaluations prior to their total knee arthroplasty. Investigators will collect clinical data for 12 months. Follow-up clinical visits include 3 and 12 months post-operatively.

The primary endpoint of this study is defined as component alignment as determined using long leg X-Rays. The secondary endpoint will be to evaluate the Knee Society Score, EQ-5D (EuroQol-5Dimensions) scoring system, operating room time, blood loss and complications

03

Conditions studied

  • Avascular Necrosis
  • Post-traumatic; Arthrosis
  • Knee Osteoarthritis

Keywords

  • primary total knee arthroplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is male or female
  • Patient needs a primary total knee replacement using the NexGen LPS Flex or Persona knee implant
  • Patient is diagnosed with non-inflammatory degenerative joint disease (e.g., osteoarthritis, post-traumatic arthritis, avascular necrosis, etc.)
  • Patient is over 18 years old
  • Patient is able to:

    • Understand what participation in the study entails and willing to consent (patient or his/her legal guardian) to participate in the study by signing and dating an IRB/EC (ethics committee) approved inform consent form, and
    • Follow surgeon/staff instructions, and
    • Return for all follow-up evaluations, and
    • Able and willing to undergo a preoperative full-leg, standing radiographs and/or CT-scan
  • Patient meets an acceptable preoperative medical clearance and is free of or treated for cardiac, pulmonary, hematological or other conditions that would pose excessive operative risk.
  • Patient has a presence of varus or valgus deformity of 15 degrees or less.

Exclusion criteria

Exclusion Criteria:

  • Patient is currently enrolled in an new drug or device study.
  • Patient has an active infection (including septic knee, distant infection, or osteomyelitis).
  • Patient has severe hip arthrosis.
  • Patient has neurological disorders (including, but not limited to Parkinson's disease).
  • Patient has had a prior ipsilateral unicompartmental knee arthroplasty, TKA, knee fusion or patellectomy.
  • Patient has hip or knee ankylosis.
  • Patient has inflammatory joint disease.
  • Patient has rheumatoid knee arthritis.
  • Patient has indications of intra- and/or extra-articular deformations that would eliminate or tend to eliminate adequate implant support or prevent the use of an appropriately sized implant, such as polio, history of tibial plateau fracture, etc.
  • Patient has any metal within 150 mm of the joint line for the operative-side knee.
  • Patient has knee deformities greater than 15 degrees of fixed varus, valgus, or flexion contracture on initial physical examination.
  • Female who is pregnant or lactating.
  • Patient currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
  • Patient has arterial disease or stents that would exclude the use of a tourniquet.
  • Patient has insufficient quality or quantity of bone to support the implant due to prior knee surgery (or surgeries), cancer, metabolic bone disease, osteoporosis/osteopenia (diagnosed or treated with medication), active/old/remote infection, etc.
  • Patient has a mental condition that may interfere with his/her ability to give an or interfere with his/her ability or willingness to fulfill the requirements of the study.
  • Patient has a condition that would place excessive demands on the implant (e.g., Charcot's joints, muscle deficiencies, multiple joint disabilities, skeletal immaturity, etc.).
  • Patient has collateral ligament insufficiency.
  • Patient has an disorder (e.g., AIDS, etc.) that would require cytotoxic drugs, , large dose of irradiation, or antilymphocytic serum.
  • Patient has an existing condition that would, in the opinion of the investigator, compromise participation or follow-up in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
72 participants (actual)

Study arms

  • Other
    iAssist group

    patients will have primary total knee arthroplasty with the iAssist. The iAssist Knee System is a computer assisted stereotaxic surgical instrument system to assist the surgeon in the positioning of orthopedic implant system components intra-operatively. It involves surgical instruments and position sensors to determine alignment axes in relation to anatomical landmarks and to precisely position alignment instruments and implant components relative to these axes.

    Procedure: total knee arthroplasty

  • Other
    conventional instrumentation

    patients will have primary total knee arthroplasty with the conventional instrumentation.

    Procedure: total knee arthroplasty

Interventions

  • Proceduretotal knee arthroplasty

    surgical procedure in which damaged parts of the knee joint are replaced with an implant.

06

What researchers measure

Primary outcomes

  1. Component Alignment

    Assess the differences in component alignment, measured by the mean of radiographs, between iASSIST™ and conventional instrumentation in primary total knee arthroplasty (TKA) procedures.

    Time frame: 1 year

Secondary outcomes

  1. Knee Society Score Assessment

    Assess the differences in Knee Society Score between iASSIST™ and conventional instrumentation in primary TKA procedures. Higher (and better) score value: 100, lower value: 0. Score 80-100 = Excellent Score 70-79 = Good Score 60-69 = Fair Score below 60 = Poor

    Time frame: 1 year

  2. Knee Society Score Function

    Knee Society Score function asses 12 months postoperatively between iASSIST™ and conventional instrumentation in primary TKA procedures. Higher (and better) score value: 100, lower value: 0. Score 80-100 = Excellent Score 70-79 = Good Score 60-69 = Fair Score below 60 = Poor

    Time frame: 1 year

  3. EQ-5D Questionnaire

    Assess the differences in EQ-5D between iASSIST™ and conventional instrumentation in primary TKA procedures at 12 months postoperatively. Comparison of the derived EQ-5D scale and health state between the 2 groups. The EQ-5D questionnaire includes five dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. EQ-5D values range from -0.2 to 1 where the negative values correspond to bad health states (states worse than death), and 1.0 corresponds to perfect health.

    Time frame: 1 year

07

Results

Posted Apr 13, 2021
Limitations and caveats
Since the first follow-up visits were performed according to the standard of care of each site, they did not occur at the same time point.

Participant flow

Participant flow — Overall Study
MilestoneiAssist GroupConventional Instrumentation Group
Started4527
Completed4426
Not completed11

Outcome measures

PrimaryComponent Alignment

Assess the differences in component alignment, measured by the mean of radiographs, between iASSIST™ and conventional instrumentation in primary total knee arthroplasty (TKA) procedures.

Time frame:
1 year
Reported as:
Mean · degree
Component Alignment
degreeiAssist GroupConventional Instrumentation Group
Component Alignment179 ± 2.9178 ± 3.9
Statistical analysis
  • iAssist Group vs Conventional Instrumentation Group · t-test, 2 sided · p = 0.2342
SecondaryKnee Society Score Assessment

Assess the differences in Knee Society Score between iASSIST™ and conventional instrumentation in primary TKA procedures. Higher (and better) score value: 100, lower value: 0. Score 80-100 = Excellent Score 70-79 = Good Score 60-69 = Fair Score below 60 = Poor

Time frame:
1 year
Reported as:
Mean · score on a scale
Knee Society Score Assessment
score on a scaleiAssist GroupConventional Instrumentation Group
Knee Society Score Assessment74.7 ± 12.572.4 ± 11.6
Statistical analysis
  • iAssist Group vs Conventional Instrumentation Group · t-test, 2 sided · p = 0.4427
SecondaryKnee Society Score Function

Knee Society Score function asses 12 months postoperatively between iASSIST™ and conventional instrumentation in primary TKA procedures. Higher (and better) score value: 100, lower value: 0. Score 80-100 = Excellent Score 70-79 = Good Score 60-69 = Fair Score below 60 = Poor

Time frame:
1 year
Reported as:
Mean · score on a scale
Knee Society Score Function
score on a scaleiAssist GroupConventional Instrumentation Group
Knee Society Score Function80.5 ± 13.878.5 ± 19.1
Statistical analysis
  • iAssist Group vs Conventional Instrumentation Group · t-test, 2 sided · p = 0.6154
SecondaryEQ-5D Questionnaire

Assess the differences in EQ-5D between iASSIST™ and conventional instrumentation in primary TKA procedures at 12 months postoperatively. Comparison of the derived EQ-5D scale and health state between the 2 groups. The EQ-5D questionnaire includes five dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. EQ-5D values range from -0.2 to 1 where the negative values correspond to bad health states (states worse than death), and 1.0 corresponds to perfect health.

Time frame:
1 year
Reported as:
Mean · score on a scale
EQ-5D Questionnaire
score on a scaleiAssist GroupConventional Instrumentation Group
EQ-5D Questionnaire0.8 ± 0.20.8 ± 0.3
Statistical analysis
  • iAssist Group vs Conventional Instrumentation Group · t-test, 2 sided · p = 0.4549

Adverse events

Collected over The adverse events were collected preoperatively, intraoperatively and postoperatively (at 3 months ±2 weeks and 12 months ±1 month postoperative).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
iAssist Group0/45 (0%)2/45 (4.4%)7/45 (15.6%)
Conventional Instrumentation Group0/27 (0%)4/27 (14.8%)3/27 (11.1%)
Most frequent serious events
Most frequent serious events
EventiAssist GroupConventional Instrumentation Group
Implant failureSurgical and medical procedures0/451/27
Pulmonary embolismVascular disorders0/451/27
Lump in the neck: metastasis,as well as in the lungsGeneral disorders0/451/27
Patella transverse fracture+dislocation of the prosthesis+tibia shaft fracture+infeSurgical and medical procedures0/451/27
Poor alignment in tibia componentSurgical and medical procedures1/450/27
Sepsis in bronchial asthma, infection exacerbationInfections and infestations1/450/27
Most frequent other events
Showing 10 of 11
Most frequent other events
EventiAssist GroupConventional Instrumentation Group
Flexion ContractureGeneral disorders1/451/27
Pain in the calf (deep vein thrombosis)Vascular disorders0/451/27
patient felt on the floor, he wanted to stand up aloneSocial circumstances0/451/27
Patient still had a joint effusion 6 months after surgerySurgical and medical procedures0/451/27
Allergic reaction after eating nutsGeneral disorders1/450/27
Allergic reaction unclear cause (itching, dyspnea, rash)General disorders1/450/27
Radius fractureSurgical and medical procedures1/450/27
Allergic reaction (Dafalgan)General disorders1/450/27
Foot fractureSurgical and medical procedures1/450/27
Delayed Wound HealingSurgical and medical procedures1/450/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)iAssist GroupConventional Instrumentation GroupTotal
Mean67.3 ± 7.970.3 ± 7.468.4 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)iAssist GroupConventional Instrumentation GroupTotal
Female301747
Male151025
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)iAssist GroupConventional Instrumentation GroupTotal
Count of participants——0
Weight kg
Weight kg(kg)iAssist GroupConventional Instrumentation GroupTotal
Mean81.4 ± 17.284.3 ± 13.082.5 ± 15.7
Body Mass Index (BMI) kg/m^2
Body Mass Index (BMI) kg/m^2(kg/m^2)iAssist GroupConventional Instrumentation GroupTotal
Mean30.4 ± 5.530.7 ± 4.630.5 ± 5.1
Height cm
Height cm(cm)iAssist GroupConventional Instrumentation GroupTotal
Mean163.5 ± 10.6166.0 ± 9.6164.5 ± 10.3
08

Study locations

3 sites
  • Hospital El Angel, S.A.
    Malaga, 29007, Spain
  • Hospital Unviersitario Son Espases
    Palma de Mallorca, 07010, Spain
  • Universitätsklinik Balgrist
    Zurich, 8008, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Dec 2018, 56 months.

Results were first posted in Apr 2021, 2 years 4 months after primary completion.

Of 45 interventional studies with no phase under Osteonecrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 91. This study's 56 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2017
First posted
Apr 12, 2017
StartActual
Apr 2014
Primary completionActual
Dec 2018
CompletionActual
Dec 2018
Results first posted
Apr 13, 2021
Last update
Apr 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03111407
Lead sponsor
Zimmer, GmbH
Responsible party
Sponsor
First posted
Apr 12, 2017
Start date
Apr 2014
Primary completion
Dec 2018
Completion
Dec 2018
Results posted
Apr 13, 2021
Last update
Apr 13, 2021

Study contacts

Paola Vivoda, Ass.Direct
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion